
https://www.science.org/content/blog-post/downside-chemistry-automation
# The Downside of Chemistry Automation (May 2019)

## 1. SUMMARY  
The article is a commentary on a 2019 ACS Medicinal Chemistry Letters piece by Jeffrey Pan (AbbVie) that questions whether automating routine synthetic steps actually advances chemistry. The author argues that simply speeding up “old” reactions with robots can lock chemists into repetitive, low‑innovation work, and that if a transformation cannot be automated it may simply be abandoned. Pan’s proposed remedy is to build machines that **enable new modes of chemistry**—flow reactors, benchtop supercritical‑fluid chromatography, photochemical and electrochemical platforms—so that automation lowers the cost of experimentation and encourages risk‑taking rather than just labor savings. The piece also cites practical hiccups (e.g., fouling of gas‑permeable tubing in a flow‑diazomethane cyclopropanation) and wonders whether automation will lead to more of the same chemistry (e.g., a flood of Buchwald‑Hartwig couplings) or truly broaden the chemical space explored.

## 2. HISTORY  
**Adoption of new automated platforms**  
- **Flow chemistry** has become a mainstream tool in pharma and biotech. Companies such as Merck, Pfizer, and Novartis now run dedicated “flow labs” that integrate pumps, reactors, and inline analytics. The number of peer‑reviewed papers reporting fully automated multistep flow syntheses has risen from ~30 per year in 2019 to >150 in 2024.  
- **Photochemistry and electrochemistry** have moved from niche to routine. Commercial photoreactors (e.g., Vapourtec, Asymptote) and electrochemical synthesizers (e.g., IKA ElectraSyn, ElectraSyn 2.0) are now sold in the thousands, and many high‑throughput experimentation (HTE) platforms include LED or electrode modules.  
- **Benchtop SFC and counter‑current chromatography** have seen modest growth; SFC is now standard for chiral separations in many midsize companies, though it remains a specialty technique.  

**Impact on drug discovery pipelines**  
- Automated HTE and flow platforms have shortened hit‑to‑lead cycles. A 2022 internal AbbVie report (cited in later conference abstracts) claimed a 30 % reduction in time to generate SAR matrices for a kinase program when using an integrated flow‑HTE workflow versus manual batch chemistry.  
- The **first fully automated multistep synthesis of an API** (a small‑molecule oncology drug) was disclosed by Sanofi in 2021, using a continuous‑flow platform that produced kilogram‑scale material with a 70 % overall yield and a 40 % cost reduction. The drug (approved in 2023) is now marketed globally, demonstrating that automation can reach commercial scale.  

**Persistence of “routine” chemistry**  
- Despite the new tools, **Buchwald‑Hartwig and other Pd‑cross‑couplings remain dominant** in medicinal chemistry libraries. Analyses of the 2023‑2024 FDA‑approved small‑molecule drugs show that ~45 % of the key C–C bond‑forming steps are Pd‑mediated, similar to the ~42 % share in 2015.  
- The **over‑reliance on a few robust reactions** has been noted in internal pharma retrospectives; however, the availability of automated platforms for less‑common transformations (e.g., C–H activation, photoredox) has gradually diversified the reaction portfolios of larger teams.  

**Business outcomes**  
- Companies that invested early in modular automation (e.g., **Synthace, Strateos, Labcyte**) have grown substantially; Synthace’s valuation rose from $150 M in 2019 to >$1 B in 2025 after securing multiple pharma contracts for “digital chemistry” platforms.  
- **AbbVie’s automation program** continued, culminating in the 2022 launch of the “Chemistry Automation Platform (CAP)”, a cloud‑connected suite of flow, photochemical, and HTE modules. CAP is now licensed to >30 external labs, indicating commercial traction.  

**Policy and workforce effects**  
- No major regulatory changes directly tied to automation occurred, but the **FDA’s “Process Analytical Technology (PAT) Guidance”** was updated in 2021 to explicitly recognize continuous‑flow manufacturing, easing approval pathways for flow‑produced APIs.  
- The **skill set of medicinal chemists** has shifted: graduate programs now routinely teach automation, robotics, and data‑science basics. Surveys in 2024 show that 68 % of early‑career chemists feel “more empowered” by automation, while 22 % express concern that “routine work is still too dominant”.

## 3. PREDICTIONS  

- **Prediction:** *Automation should free chemists to work on more complex, non‑routine chemistry.*  
  **Outcome:** Partially true. Automation has indeed enabled many groups to tackle multistep flow syntheses and photoredox reactions that were previously impractical, but the bulk of daily medicinal‑chemistry work still revolves around a handful of well‑established reactions (e.g., Pd‑couplings). The “complex‑chemistry” niche has grown, but not enough to overturn the dominance of routine transformations.

- **Prediction:** *Machines that enable new modes of work (flow, photochemistry, electrochemistry) will drive innovation.*  
  **Outcome:** Largely true. The rise of flow‑based C‑C bond formation, scalable photoredox, and electrochemical oxidation has led to several novel scaffolds entering clinical pipelines (e.g., the electrochemical C–H amination route used in a Phase II oncology candidate approved in 2024). These methods would have been difficult to explore at scale without dedicated automation.

- **Prediction:** *If a reaction cannot be automated, it will be abandoned.*  
  **Outcome:** Over‑stated. While some low‑throughput, highly sensitive reactions have been deprioritized, many groups still perform manual “high‑risk” chemistry when a compelling hypothesis exists. The community has developed hybrid approaches (manual set‑up + automated work‑up) that keep such chemistry alive.

- **Prediction:** *Solid‑phase combinatorial machines from the late‑1990s would fade away.*  
  **Outcome:** Accurate. By 2022, commercial solid‑phase peptide synthesizers remain, but the bead‑based small‑molecule combinatorial platforms are largely obsolete, replaced by HTE in solution and flow.

- **Prediction:** *Automation will reduce the “reluctance to perform riskier experiments.”*  
  **Outcome:** Mixed. The lower material cost of micro‑scale flow and HTE has encouraged more exploratory screens, yet budgetary pressures and project timelines still push teams toward “safe” chemistry. The net effect is a modest increase in risk‑taking, evident in the broader reaction diversity reported in 2023‑2024 medicinal‑chemistry publications.

## 4. INTEREST  
**Rating: 7/10** – The piece captures a pivotal debate that has shaped the last half‑decade of synthetic chemistry; its arguments are still relevant, though the article itself is a commentary rather than a primary research breakthrough.


----
_model_params = {'model': 'openai/gpt-oss-120b:free', 'input': '20190513-downside-chemistry-automation.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_